Bio-Rad Laboratories Statistics
Total Valuation
BIO has a market cap or net worth of $6.80 billion. The enterprise value is $6.51 billion.
Important Dates
The next confirmed earnings date is Thursday, May 1, 2025, after market close.
| Earnings Date | May 1, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BIO has 28.01 million shares outstanding. The number of shares has decreased by -3.41% in one year.
| Current Share Class | 22.94M |
| Shares Outstanding | 28.01M |
| Shares Change (YoY) | -3.41% |
| Shares Change (QoQ) | +0.04% |
| Owned by Insiders (%) | 16.03% |
| Owned by Institutions (%) | 67.70% |
| Float | 19.44M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 25.48 |
| PS Ratio | 2.67 |
| Forward PS | 2.63 |
| PB Ratio | 1.03 |
| P/TBV Ratio | 1.16 |
| P/FCF Ratio | 23.47 |
| P/OCF Ratio | 14.93 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 15.47, with an EV/FCF ratio of 22.47.
| EV / Earnings | n/a |
| EV / Sales | 2.54 |
| EV / EBITDA | 15.47 |
| EV / EBIT | 24.19 |
| EV / FCF | 22.47 |
Financial Position
The company has a current ratio of 6.48, with a Debt / Equity ratio of 0.21.
| Current Ratio | 6.48 |
| Quick Ratio | 4.55 |
| Debt / Equity | 0.21 |
| Debt / EBITDA | 2.80 |
| Debt / FCF | 4.75 |
| Interest Coverage | 5.50 |
Financial Efficiency
Return on equity (ROE) is -24.09% and return on invested capital (ROIC) is 1.86%.
| Return on Equity (ROE) | -24.09% |
| Return on Assets (ROA) | 1.55% |
| Return on Invested Capital (ROIC) | 1.86% |
| Return on Capital Employed (ROCE) | 3.02% |
| Revenue Per Employee | $333,312 |
| Profits Per Employee | -$239,506 |
| Employee Count | 7,700 |
| Asset Turnover | 0.24 |
| Inventory Turnover | 1.54 |
Taxes
| Income Tax | -498.30M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -12.74% in the last 52 weeks. The beta is 1.12, so BIO's price volatility has been higher than the market average.
| Beta (5Y) | 1.12 |
| 52-Week Price Change | -12.74% |
| 50-Day Moving Average | 254.12 |
| 200-Day Moving Average | 313.98 |
| Relative Strength Index (RSI) | 47.13 |
| Average Volume (20 Days) | 397,213 |
Short Selling Information
The latest short interest is 1.13 million, so 4.03% of the outstanding shares have been sold short.
| Short Interest | 1.13M |
| Short Previous Month | 1.00M |
| Short % of Shares Out | 4.03% |
| Short % of Float | 5.81% |
| Short Ratio (days to cover) | 2.47 |
Income Statement
In the last 12 months, BIO had revenue of $2.57 billion and -$1.84 billion in losses. Loss per share was -$65.36.
| Revenue | 2.57B |
| Gross Profit | 1.38B |
| Operating Income | 269.00M |
| Pretax Income | -1.73B |
| Net Income | -1.84B |
| EBITDA | 420.60M |
| EBIT | 269.00M |
| Loss Per Share | -$65.36 |
Full Income StatementBalance Sheet
The company has $1.66 billion in cash and $1.37 billion in debt, giving a net cash position of $289.80 million or $10.35 per share.
| Cash & Cash Equivalents | 1.66B |
| Total Debt | 1.37B |
| Net Cash | 289.80M |
| Net Cash Per Share | $10.35 |
| Equity (Book Value) | 6.57B |
| Book Value Per Share | 234.52 |
| Working Capital | 2.56B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $455.20 million and capital expenditures -$165.60 million, giving a free cash flow of $289.60 million.
| Operating Cash Flow | 455.20M |
| Capital Expenditures | -165.60M |
| Free Cash Flow | 289.60M |
| FCF Per Share | $10.34 |
Full Cash Flow StatementMargins
Gross margin is 53.73%, with operating and profit margins of 10.48% and -71.86%.
| Gross Margin | 53.73% |
| Operating Margin | 10.48% |
| Pretax Margin | -91.27% |
| Profit Margin | -71.86% |
| EBITDA Margin | 16.39% |
| EBIT Margin | 10.48% |
| FCF Margin | 11.28% |
Dividends & Yields
BIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 3.41% |
| Shareholder Yield | n/a |
| Earnings Yield | -27.14% |
| FCF Yield | 4.26% |
Dividend DetailsAnalyst Forecast
The average price target for BIO is $396.50, which is 63.32% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $396.50 |
| Price Target Difference | 63.32% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 3.67% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on March 8, 2002. It was a forward split with a ratio of 2:1.
| Last Split Date | Mar 8, 2002 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
BIO has an Altman Z-Score of 3.75 and a Piotroski F-Score of 6.
| Altman Z-Score | 3.75 |
| Piotroski F-Score | 6 |